Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
American College of Physicians
Rifaximin shows sustained benefit against irritable bowel syndrome
November 7th, 2006
A new study found that patients reported greater global improvements in irritable bowel syndrome (IBS) symptoms and less bloating after taking rifaximin than patients taking placebo. The randomized, double-blind study is the first to demonstrate a sustained benefit of an antibiotic for IBS symptoms after treatment is stopped. The study, "The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowl Syndrome," is published in a recent issue of Annals of Internal Medicine. IBS is one of the most common chronic medical conditions - affecting about 15 to 20% of the population. Its cause is unknown but some IBS...
Source: Drug Law Weekly (2006-11-07)
|
